Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 2
1951 2
1952 3
1954 1
1956 1
1958 1
1961 1
1963 1
1964 1
1966 1
1968 1
1978 1
1979 2
1980 2
1981 1
1983 1
1986 1
1991 1
1993 1
1994 1
1995 2
1997 4
1998 1
1999 2
2000 1
2001 1
2002 1
2003 4
2005 1
2006 1
2007 6
2008 4
2009 5
2010 5
2011 4
2012 4
2014 4
2015 3
2016 10
2017 5
2018 6
2019 9
2020 4
2021 6
2022 6
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. Among authors: mcarthur h. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549. N Engl J Med. 2020. PMID: 32101663 Clinical Trial.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. Among authors: mcarthur h. N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651. N Engl J Med. 2022. PMID: 35139274 Clinical Trial.
Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer.
Shiao SL, Gouin KH 3rd, Ing N, Ho A, Basho R, Shah A, Mebane RH, Zitser D, Martinez A, Mevises NY, Ben-Cheikh B, Henson R, Mita M, McAndrew P, Karlan S, Giuliano A, Chung A, Amersi F, Dang C, Richardson H, Shon W, Dadmanesh F, Burnison M, Mirhadi A, Zumsteg ZS, Choi R, Davis M, Lee J, Rollins D, Martin C, Khameneh NH, McArthur H, Knott SRV. Shiao SL, et al. Among authors: mcarthur h. Cancer Cell. 2024 Jan 8;42(1):70-84.e8. doi: 10.1016/j.ccell.2023.12.012. Cancer Cell. 2024. PMID: 38194915
Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Takahashi M, Cortés J, Dent R, Pusztai L, McArthur H, Kümmel S, Denkert C, Park YH, Im SA, Ahn JH, Mukai H, Huang CS, Chen SC, Kim MH, Jia L, Li XT, Tryfonidis K, Karantza V, Iwata H, Schmid P. Takahashi M, et al. Among authors: mcarthur h. JAMA Netw Open. 2023 Nov 1;6(11):e2342107. doi: 10.1001/jamanetworkopen.2023.42107. JAMA Netw Open. 2023. PMID: 37966841 Free PMC article. Clinical Trial.
Immunotherapy in Breast Cancer: the New Frontier.
Hu ZI, McArthur HL. Hu ZI, et al. Among authors: mcarthur hl. Curr Breast Cancer Rep. 2018;10(2):35-40. doi: 10.1007/s12609-018-0274-y. Epub 2018 Apr 16. Curr Breast Cancer Rep. 2018. PMID: 29881518 Free PMC article. Review.
Optimizing (neo)adjuvant treatment of HER2-positive breast cancer.
Basho RK, McArthur HL. Basho RK, et al. Among authors: mcarthur hl. Ther Adv Med Oncol. 2018 Jun 24;10:1758835918775697. doi: 10.1177/1758835918775697. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 30034547 Free PMC article. Review.
Autophagy receptor NDP52 alters DNA conformation to modulate RNA polymerase II transcription.
Dos Santos Á, Rollins DE, Hari-Gupta Y, McArthur H, Du M, Ru SYZ, Pidlisna K, Stranger A, Lorgat F, Lambert D, Brown I, Howland K, Aaron J, Wang L, Ellis PJI, Chew TL, Martin-Fernandez M, Pyne ALB, Toseland CP. Dos Santos Á, et al. Among authors: mcarthur h. Nat Commun. 2023 May 18;14(1):2855. doi: 10.1038/s41467-023-38572-9. Nat Commun. 2023. PMID: 37202403 Free PMC article.
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.
Pusztai L, Denkert C, O'Shaughnessy J, Cortes J, Dent R, McArthur H, Kümmel S, Bergh J, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Zhu Y, Pan W, Tryfonidis K, Schmid P. Pusztai L, et al. Among authors: mcarthur h. Ann Oncol. 2024 Feb 17:S0923-7534(24)00046-2. doi: 10.1016/j.annonc.2024.02.002. Online ahead of print. Ann Oncol. 2024. PMID: 38369015
128 results